STIMULATOR, ELECTRICAL, IMPLANTED, FOR PARKINSONIAN TREMOR
Report
- Report Number
- 3007566237-2016-02679
- Event Type
- Injury
- Date Received
- July 19, 2016
- Date of Event
- January 1, 2003
- Report Date
- July 19, 2016
- Manufacturer
- MEDTRONIC NEUROMODULATION
- Product Code
- MHY
- PMA / PMN Number
- P960009
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- IN
- Reporter Occupation
- PHYSICIAN
Narratives
CONCOMITANT MEDICAL PRODUCTS: PRODUCT ID 3389. EVENT DATE IS APPROXIMATE. YEAR VALID. A GOOD FAITH EFFORT WILL BE MADE TO OBTAIN THE APPLICABLE INFORMATION RELEVANT TO THE REPORT. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
DOSHI, P. K., CHHAYA, N. A., BHATT, M. A. BILATERAL SUBTHALAMIC NUCLEUS STIMULATION FOR PARKINSON'S DISEASE. NEUROL INDIA. 2003; 51(1): 43-48. HTTP://LIBCONTENT.MEDTRONIC.COM:2133/PUBMED/12865514 SUMMARY: HIGH FREQUENCY STIMULATION OF THE SUBTHALAMIC NUCLEUS (STN) IS KNOWN TO AMELIORATE THE SIGNS AND SYMPTOMS OF ADVANCED PARKINSON¿S DISEASE. WE STUDIED THE EFFECT OF HIGH FREQUENCY STN STIMULATION IN 23 PATIENTS. TWENTY-TREE PATIENT¿S SUFFERING FROM SEVERE PARKINSON¿S DISEASE (STAGES III-V ON HOEHN AND YAHR SCALE) AND PARTICULARLY BRADYKINESIA, RIGIDITY, LEVODOPA-INDUCED DYSKINESIAS UNDERWENT BILATERALIMPLANTATION OF ELECTRODES IN THE STN. PREOPERATIVE AND POST-OPERATIVE ASSESMENTS OF THESE PATIENT¿S AT 1, 3, 6, AND 12 MONTHS FOLLOW UP IN ¿ON¿ AND ¿OFF¿ DRUG CONDITIONS WAS CARRIED OUT USING UNIFIED PARKINSON¿S DISEASE RATING SCALE, HOEHN AND YAHR STAGING, ENGLAND ACTIVITIES OF DAILY LIVING SCORE AND VIDEO RECORDINGS. AFTER ONE YEAR OF ELECTRICAL STIMULATION OF THE STN, THE PATIENT¿S SCORES FOR ACTIVITIES OF DAILY LIVING AND MOTOR EXAMINATION SCORES (UNIFIED PARKINSON¿S DISEASE RATING SCALE PARTS II AND III) OFF MEDICATION IMPROVED BY 62% AND 61%RESPECTIVELY (P<(><<)>0.0005). THE SUBSCORES FOR THE AKINESIA RIGIDITY, TREMOR AND GAIT ALSO IMPROVED. (P<(><<)>0.0005). THE AVERAGE AGE LEVODOPA DOSE DECREASED FROM 813 MG TO 359 MG. THE COGNITIVE FUNCTIONS REMAINED UNCHANGED. TWO PATIENTS DEVELOPED DEVICE RELATED COMPLICATIONS AND TWO PATIENTS EXPERIENCED ABNORMAL WEIGHT GAIN. BILATERAL SUBTHALAMIC NUCLEUS STIMULATION IS AN EFFECTIVE TREATMENT FOR ADVANCED PARKINSON¿S DISEASE. IT REDUCES THE SEVERITY OF ¿OFF¿ PHASE SYMPTOMS, IMPROVES AXIAL SYMPTOMS AND REDUCES LEVODOPA REQUIREMENTS. THE REDUCTION IN LEVODOPA DOSE IS USEFUL IN CONTROLLING DRUG-INDUCED DYSKINESIAS. REPORTED EVENTS: 1 MALE PATIENT SUFFERING FROM SEVERE PARKINSON¿S DISEASE, AND PARTICULARLY BRADYKINESIA, RIGIDITY, AND LEVODOPA-INDUCED DYSKINESIAS UNDERWENT DEEP BRAIN STIMULATION AND DEVELOPED DEVICE-RELATED COMPLICATIONS. IT WAS NOTED THE DIABETIC PATIENT DEVELOPED ¿DOUBTFUL¿ INFECTION AT THE SCALP CONNECTOR SITE WHERE HE WAS HOSPITALIZED IMMEDIATELY AND SUCCESSFULLY TREATED WITH INTRAVENOUS ANTIBIOTICS; 1 MALE PATIENT SUFFERING FROM SEVERE PARKINSON¿S DISEASE, AND PARTICULARLY BRADYKINESIA, RIGIDITY, AND LEVODOPA-INDUCED DYSKINESIAS UNDERWENT DEEP BRAIN STIMULATION AND DEVELOPED DEVICE-RELATED COMPLICATIONS. IT WAS NOTED THE PATIENT INJURED HIMSELF OVER THE NEUROSTIMULATOR AND DEVELOPED BREACH IN THE SKIN EXPOSING THE DEVICE. THE DEVICE WAS EXPLANTED AND THE PATIENT WAS TREATED WITH INTRAVENOUS ANTIBIOTICS. THE DEVICE WAS IMPLANTED ON THE RIGHT SIDE AFTER HEALING OF THE LEFT SIDE WOUND. FURTHER INFORMATION HAS BEEN REQUESTED; A SUPPLEMENTAL REPORT WILL BE SUBMITTED IF ADDITIONAL INFORMATION IS RECEIVED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 457332 | STIMULATOR, ELECTRICAL, IMPLANTED, FOR PARKINSONIAN TREMOR | MHY | MEDTRONIC NEUROMODULATION | NEU_INS_STIMULATOR | UNKNOWN |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | Hospitalization| R |